Division of Tuberculosis Elimination (DTBE) Strategic Plan 2022-2026

Doctor and patient

Despite being preventable and curable, tuberculosis (TB) remains one of the world’s leading infectious disease killers affecting millions around the world, including here in the United States.

Since 1953, in cooperation with state and local health departments, the United States national TB program has collected information on each newly reported case of TB disease in the United States.

Although the United States has reported record low cases, too many people still suffer from TB disease in this country and up to 13 million people have latent TB infection. Without treatment, those with latent TB infection are at risk for developing TB disease in the future.

CDC’s work in the United States supports a dual approach to find and treat active TB disease and test for and treat latent TB infection to prevent progression to disease.

Read the full Division of Tuberculosis Elimination Strategic Plan 2022-2026.

Elimination of TB in the United States (defined as <1 case/million persons annually)

To promote health and quality of life by preventing, controlling, and eventually eliminating TB in the United States.

Reduce TB morbidity in the United States with a particular focus on reducing disparities in TB morbidity among disproportionately affected groups, including non–U.S.-born persons and racial and ethnic minority groups.

Overarching Tactics

DTBE plans to increase emphasis or develop new activities in following areas:

Sustain commitment
Make the argument: Publish additional studies on cost effectiveness, costs of treatment, and return on investments
Maintain basic TB control functions
Expand effective latent TB infection testing and treatment strategies
Maintain or increase focus on prevention of TB disease in the United States for non-U.S.-born persons
Maximize impact of limited resources